Andrew J. Roth


Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment

October 6th 2016

William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.

TNBC Subgroup Stands to Benefit From Androgen Receptor Antagonists

October 3rd 2016

Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.

Treatment Paradigm for TNBC Continues to Evolve

October 3rd 2016

With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.

Expert Describes Potential Therapeutic Vaccine for Advanced HCC

September 12th 2016

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC

September 11th 2016

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

Regorafenib Poised as Second-Line Standard of Care in HCC

September 10th 2016

Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.

Midostaurin Shows Promise in Advanced Mastocytosis Trial

August 27th 2016

The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.

FDA Approves Dronabinol Solution to Treat CINV

August 3rd 2016

A dronabinol oral solution (Syndros) has been approved by the FDA as a treatment for patients with chemotherapy-induced nausea and vomiting (CINV) in those who have not responded to conventional antiemetic therapies.

Early Integration of Palliative Care Improves Outcomes for Family Caregivers

May 19th 2016

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

Proactive, Team-Based Approach Leads to Better Care, Fewer Treatment Delays for Head and Neck Cancer Patients

April 28th 2016

A multidisciplinary team led by oncology nurses can reduce both hospitalization and treatment breaks for patients with head and neck cancer.

Phone Calls May Help Assess, Improve Oral Cancer Therapy Adherence

April 28th 2016

With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.

Optimizing Current Treatments for CLL as New Agents Are Investigated

April 2nd 2016

Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.

“Forgotten Lessons” May Help Advance Colorectal Cancer Care

March 31st 2016

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

TILs Advancing as Melanoma Immunotherapy Option

March 31st 2016

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

Expert Discusses Emerging Agents in ER+ Metastatic Breast Cancer

March 23rd 2016

Joyce O’Shaughnessy, MD, discusses how four agents—palbociclib (Ibrance), pembrolizumab (Keytruda), abemaciclib (LY2835219), and buparlisib (BKM120)—are worth examining in estrogen receptor-positive breast cancer.

World Cancer Day Aims to Unite Millions to Increase Awareness, Reduce Global Burden

February 4th 2016

With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.

Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma

December 4th 2015

Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.

New Model Supports Use of Palliative Care With Radiotherapy for Bone Metastases

December 4th 2015

A novel service model that incorporated palliative care measures and shorter radiation treatment was associated with fewer unfinished treatments with radiation, shorter hospital stays, and increased use of palliative care for patients with bone metastases.

June Provides Insight Into Managing AEs From CAR T-Cell Therapies

November 21st 2015

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

Large Study Adds Clarity to Use of Docetaxel With Standard Care in Advanced, Hormone-Naïve Prostate Cancer

May 13th 2015

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.